Maria Fardis - 03 Aug 2026 Form 4 Insider Report for Obsidian Therapeutics, Inc. (OBX)

Reporting relationship: Director
Issuer ticker: OBX
Reported as of: 03 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2026, 16:05:22 UTC
Prior SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Gabriela Morales-Rivera, Attorney-in-Fact

Key filing fact

Maria Fardis filed Form 4 for Obsidian Therapeutics, Inc. (OBX) on 05 Aug 2026.

Key facts

This page summarizes Maria Fardis's Form 4 filing for Obsidian Therapeutics, Inc. (OBX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Aug 2026, 16:05.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559231 Primary reporting owner

Fardis Maria

Relationship: Director
Address: C/O OBSIDIAN THERAPEUTICS, INC., 1030 MASSACHUSETTS AVE, CAMBRIDGE
Signature: /s/ Gabriela Morales-Rivera, Attorney-in-Fact
Signature date: 05 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OBX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +37,653
Change %
Price: $0.000000^*
Shares after: 37,653
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,653
Exercise price: $12.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.